+86-28-82633987sales@biopurify.com
cnen
  • iso9001 iso9001
  • iso17025 iso17025
  • usp usp
Alternate Text
Home > Literature List > Inhibition of Cancer Angiogenesis Using Triptolide Nanoparticles

Inhibition of Cancer Angiogenesis Using Triptolide Nanoparticles

Journal name:J BIOMED NANOTECHNOL.
Literature No.:
Literature Url: http://www.ingentaconnect.com/content/asp/jbn/2015/00000011/00000005/art00005
Date publication:2015 May.

Authors: Wang, Cheng; Shan, Ying; Yang, Jiuli; Xu, Xuelian; Zhuang, Bo; Fan, Yingfang; Xu,Wei;

Abstract:

Tumor-associated angiogenesis is triggered by multiple angiogenic factors. Vascular endothelial growth factor blockers are currently a major mechanism of angiogenesis inhibition; however, either insensitivity due to the targeting of single angiogenic factors or serious side effects due to non-specific exposure ultimately leads to the failure of treatment. The herb-derived compound triptolide (TP) can inhibit tumor growth through multiple mechanisms. However, its hydrophobicity and side effects have hindered its translation to the clinic. Here, we have prepared TP-polymeric micelles (TP-PMs) using methoxy poly(ethylene glycol)block poly( -caprolactone). The drug loading efficiency and encapsulation efficiency can reach 7.2±0.10% and 99.1±1.05%, respectively. The TP-PM solution consisted of monodispersed particles (PDI = 0.100±0.023), which were 53.1±1.2 nm in size. In vitro release profiles indicated that the TP-PM solution exhibited 

triptolide (TP, Purity > 99%) was purchased from Chengdu Biopurify Phytochemi- cals Co, Ltd. ..

Related Products